Clinical Trials
- Brain and Other Nervous System Cancers
Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma
- Date06/17/2020
- Brain and Other Nervous System Cancers, Pediatric Cancers
A Target Validation/Phase1 Study of BGB-290 in Combination With Temozolomide in Adolescent and Young Adult IDH1/2 Newly Diagnosed and Recurrent Mutant Gliomas
- Date05/17/2022
- Brain and Other Nervous System Cancers
Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared With Fractionated SRS for Resected Metastatic Brain Disease
- Date06/06/2022
- Brain and Other Nervous System Cancers
A Phase 1 Trial to Evaluate the Safety and Tolerability of Fb-PMT in Patients With Recurrent Glioblastoma
- Date05/12/2022
- Brain and Other Nervous System Cancers
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Enzastaurin Added to Temozolomide During and Following Radiation Therapy in Newly Diagnosed Glioblastoma Patients Who Possess the Novel Genomic Biomarker DGM1
- Date06/06/2022
- Brain and Other Nervous System Cancers
A Multi-Center Phase 0/I Trial of Anti-TIGIT Antibody AB154 in Combination With Anti-PD-1 Antibody AB122 for Recurrent Glioblastoma
- Date07/01/2022
- Head and Neck Cancers
Phase II Randomized Trial of Adjuvant Radiotherapy With or Without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Date05/10/2022
- Gynecological Cancers, Other Cancers
Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
- Date05/27/2022
- Brain and Other Nervous System Cancers, Pediatric Cancers
Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma
- Ages1 year 5 months and younger
- GenderBoth
- Date05/27/2022
An Open-label, Single-arm, Single-dose, Prospective, Multicenter Phase 3 Study to Establish the Diagnostic Performance of 18F-Fluciclovine Positron Emission Tomography (PET) in Detecting Recurrent Brain Metastases After Radiation Therapy
- Ages18 years and older
- GenderBoth
- Date11/09/2020